Please Wait.....
Report
MEA Laboratory-Developed Tests (LDTs) Market - Industry Trends and Forecast to 2030
Market Report I 2023-06-01 I 318 Pages I Data Bridge Market Research
The Middle East and Africa Laboratory-Developed Tests (LDTs) Marketis expected to reach USD 1,087.71 Million by 2030 from USD 615.38 Million in 2022, growing at a CAGR of 7.4% during the forecast period of 2023 to 2030.
Market Segmentation
Europe Laboratory-Developed Tests (LDTs) Market, By Test Type (Clinical Chemistry and Immunology, Critical Care, Hematology, Molecular Diagnostics, Microbiology, and Other Test), Product Type (Consumables, Analyzers and Instruments, and Accessories), Sample Type (Blood, Urine, Tissue, Cerebrospinal Fluid (CSF), and Others), Therapeutic Area (Infections, Genetic Disorders, Oncology/Cancer, Autoimmune Disease, Urology, Gynecology, and Others), Gender (Male, and Female), Age Group (Geriatrics, Adult, and Pediatric), End Users (Hospital-Based Labs, Stand-Alone Labs, Diagnostic Chains, Academic Institutes, Clinical Research Organizations, Specialty Diagnostic Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributors, and Others), Country (Saudi Arabia, South Africa, UAE, Egypt, Israel, Rest of Middle East and Africa) - Industry Trends and Forecast to 2030
Overview of Middle East and Africa Laboratory-Developed Tests (LDTs) Market Dynamics
Drivers
- Increasing demand for personalized medicines
- Advancements in molecular diagnostics
Restraint
- Stringent quality control and standardization for LDTs
Opportunity
- Increasing demand for precision medicine and targeted therapy
Market Players
Some of the major market players operating in the Middle East and Africa Laboratory-Developed Tests (LDTs) market are:
- F. Hoffmann-La Roche Ltd
- bioMerieux, Inc.
- Sysmex Corporation
- Biomerica, Inc.
- Bio-Rad Laboratories, Inc.
- Abbott
- Siemens Medical Solutions USA, Inc.
- Quest Diagnostics Incorporated
- QIAGEN
- Eurofins Scientific
- Biodesix.
- Hologic, Inc.
- Guardant Health
- OPKO Health, Inc.
- BD
- Beckman Coulter, Inc.
- NeoGenomics Laboratories.
- Seegene Inc.
- BGI
- Milab Scientific.
- 23andMe, Inc.
- Agendia
TABLE OF CONTENTS
1 INTRODUCTION 66
1.1 OBJECTIVES OF THE STUDY 66
1.2 MARKET DEFINITION 66
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET 66
1.4 CURRENCY AND PRICING 68
1.5 LIMITATIONS 68
1.6 MARKETS COVERED 68
2 MARKET SEGMENTATION 73
2.1 MARKETS COVERED 73
2.2 GEOGRAPHICAL SCOPE 74
2.3 YEARS CONSIDERED FOR THE STUDY 75
2.4 DBMR TRIPOD DATA VALIDATION MODEL 76
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 79
2.6 MULTIVARIATE MODELLING 80
2.7 TEST TYPE SEGMENT LIFELINE CURVE 80
2.8 MARKET END USER COVERAGE GRID 81
2.9 DBMR MARKET POSITION GRID 82
2.10 VENDOR SHARE ANALYSIS 83
2.11 SECONDARY SOURCES 84
2.12 ASSUMPTIONS 84
3 EXECUTIVE SUMMARY 85
4 PREMIUM INSIGHTS 88
4.1 PESTEL ANALYSIS 89
4.2 PORTER'S FIVE FORCES MODEL 90
5 INDUSTRY INSIGHTS 91
6 NUMBER OF LABS 93
6.1 NUMBER OF LABS IN MIDDLE EASTERN COUNTRIES 93
6.2 NUMBER OF LABS IN EUROPE 93
7 REGULATIONS OF THE MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET 95
7.1 SOUTH AFRICA 95
8 MARKET OVERVIEW 96
8.1 DRIVERS 98
8.1.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 98
8.1.2 ADVANCEMENTS IN MOLECULAR DIAGNOSTICS 98
8.1.3 GROWING PREVALENCE OF CHRONIC DISEASES 98
8.1.4 INCREASING AWARENESS AND ACCEPTANCE TOWARDS THE ASSISTANCES OF LDTS 99
8.2 RESTRAINTS 99
8.2.1 STRINGENT QUALITY CONTROL AND STANDARDIZATION FOR LDTS 99
8.2.2 STRICT REGULATORY GUIDELINES REGARDING LDTS 100
8.3 OPPORTUNITIES 100
8.3.1 INCREASING DEMAND FOR PRECISION MEDICINE AND TARGETED THERAPY 100
8.3.2 ENHANCED HEALTHCARE SUBSTRUCTURE 101
8.4 CHALLENGES 101
8.4.1 DEPRIVED DATA INTERPRETATION AND INTEGRATION 101
8.4.2 COMPLEX LABORATORY PROCESSES 102
9 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE 103
9.1 OVERVIEW 104
9.2 CLINICAL CHEMISTRY AND IMMUNOLOGY 107
9.2.1 GLUCOSE 108
9.2.1.1 GLUCOSE CHALLENGE TEST 108
9.2.1.2 ORAL GLUCOSE TOLERANCE TEST (OGTT) 108
9.2.2 PROTHROMBIN 109
9.2.3 METABOLIC PANEL 109
9.2.3.1 BASIC 109
9.2.3.2 COMPREHENSIVE 109
9.2.4 LIPID PANEL 109
9.2.5 LIVER PANEL 109
9.2.5.1 ALP TEST (ALKALINE PHOSPHATE) 110
9.2.5.2 ALT TEST (ALKALINE TRANSMINASE) 110
9.2.5.3 AST TEST (ASPARTATE AMINOTRANSFERASE) 110
9.2.5.4 GAMMA-GLUTAMYL TRANSFERASE (GGT) TEST 110
9.2.6 THYROID STIMULATING HORMONE 110
9.2.7 URINALYSIS 110
9.2.7.1 RED BLOOD CELL URINE TEST 111
9.2.7.2 GLUCOSE URINE TEST 111
9.2.7.3 PROTEIN URINE TEST 111
9.2.7.4 URINE PH LEVEL 111
9.2.7.5 KETONES URINE TEST 111
9.2.7.6 BILIBURIN URINE TEST 111
9.2.7.7 URINE SPECIFIC GRAVITY TEST 112
9.2.8 OTHERS 112
9.3 CRITICAL CARE 112
9.3.1 CARBOXYHAEMOGLOBIN TEST 113
9.3.2 PH TEST 113
9.3.3 POTASSIUM TEST 113
9.3.4 SODIUM TEST 113
9.3.5 METHEMOGLOBIN TEST 113
9.3.6 LACTATE TEST 113
9.3.7 OTHERS 114
9.4 HAEMATOLOGY 114
9.4.1 COMPLETE BLOOD COUNT (CBC) 115
9.4.1.1 WHITE BLOOD CELL COUNT (WBC) 115
9.4.1.2 RED BLOOD CELL COUNT (RBC) 115
9.4.2 PLATELET COUNT 115
9.4.3 BLOOD PROTEIN TESTING 116
9.4.4 OTHERS 116
9.5 MOLECULAR DIAGNOSTIC 116
9.5.1 SAMPLE TYPE 117
9.5.1.1 BLOOD 117
9.5.1.2 URINE 117
9.5.1.3 TISSUE 117
9.5.1.4 CEREBROSPINAL FLUID (CSF) 117
9.5.1.5 OTHERS 117
9.5.2 THERAPEUTIC AREA 117
9.5.2.1 INFECTIONS 118
9.5.2.2 GENETIC DISORDERS 118
9.5.2.3 ONCOLOGY/CANCER 118
9.5.2.4 AUTOIMMUNE DISEASE 118
9.5.2.5 UROLOGY 118
9.5.2.6 GYNECOLOGY 118
9.5.2.7 OTHERS 118
9.5.3 TECHNOLOGY 119
9.5.3.1 POLYMERASE CHAIN REACTION (PCR) 119
9.5.3.2 NEXT-GENERATION SEQUENCING (NGS) 119
9.5.3.3 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 119
9.5.3.4 SANGER SEQUENCING 119
9.5.3.5 MICROARRAYS 119
9.5.3.6 MASS SPECTROMETRY 120
9.5.3.7 ISOTHERMAL AMPLIFICATION 120
9.5.4 END USER 120
9.5.4.1 HOSPITAL-BASED LABS 120
9.5.4.2 STAND-ALONE LABS 120
9.5.4.3 DIAGNOSTIC CHAINS 120
9.5.4.4 ACADEMIC INSTITUTES 121
9.5.4.5 CLINICAL RESEARCH ORGANIZATIONS 121
9.5.4.6 SPECIALTY DIAGNOSTIC CENTERS 121
9.5.4.7 OTHERS 121
9.6 MICROBIOLOGY 121
9.6.1 MICROSCOPY 122
9.6.2 CULTURE 122
9.6.3 ANTIMICROBIAL SUSCEPTIBILITY TEST 122
9.6.4 OTHERS 122
9.7 OTHER TEST 123
9.7.1 DRUGS OF ABUSE TESTING 124
9.7.2 HEPATITIS 124
9.7.3 HUMAN IMMUNODEFICIENCY VIRUSES (HIV) 124
9.7.4 MALARIA 124
9.7.5 TUBERCULOSIS 124
9.7.6 HUMAN PAPILLOMAVIRUS (HPV) 124
9.7.7 OTHERS 125
10 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE 126
10.1 OVERVIEW 127
10.2 CONSUMABLES 130
10.2.1 PANELS 130
10.2.2 REAGENT AND KITS 131
10.2.3 OTHERS 131
10.3 ANALYZERS AND INSTRUMENTS 131
10.3.1 FULLY-AUTOMATED INSTRUMENTS 132
10.3.2 SEMI-AUTOMATED INSTRUMENTS 132
10.3.3 OTHERS 132
10.4 ACCESSORIES 132
11 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE 134
11.1 OVERVIEW 135
11.2 BLOOD 138
11.3 URINE 138
11.4 TISSUE 139
11.5 CEREBROSPINAL FLUID (CSF) 139
11.6 OTHERS 140
12 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA 142
12.1 OVERVIEW 143
12.2 INFECTIONS 146
12.2.1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 147
12.2.2 CLOSTRIDIUM DIFFICILE 147
12.2.3 VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE) 147
12.2.4 CARBAPENEM-RESISTANT BACTERIA 147
12.2.5 FLU 147
12.2.6 RESPIRATORY SYNCYTIAL VIRUS (RSV) 148
12.2.7 CANDIDA 148
12.2.8 TUBERCULOSIS AND DRUG-RESISTANT TBA 148
12.2.9 MENINGITIS 148
12.2.10 GASTROINTESTINAL PANEL TESTING 148
12.2.11 CHLAMYDIA 148
12.2.12 GONORRHEA 148
12.2.13 HIV 148
12.2.14 HEPATITIS B 148
12.2.15 HEPATITIS C 148
12.2.16 OTHER INFECTIOUS DISEASES 148
12.3 GENETIC DISORDERS 149
12.3.1 NEW BORN SCREENING 149
12.3.2 PREDICTIVE AND PRESYMPTOMATIC TESTING 150
12.3.3 OTHER GENETIC TESTING 150
12.4 ONCOLOGY/CANCER 150
12.4.1 BREAST CANCER 151
12.4.2 PROSTATE CANCER 151
12.4.3 COLORECTAL CANCER 151
12.4.4 CERVICAL CANCER 151
12.4.5 KIDNEY CANCER 151
12.4.6 LIVER CANCER 151
12.4.7 BLOOD CANCER 151
12.4.8 LUNG CANCER 152
12.4.9 OTHER CANCER 152
12.5 AUTOIMMUNE DISEASE 152
12.6 UROLOGY 152
12.7 GYNECOLOGY 153
12.8 OTHERS 154
13 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER 155
13.1 OVERVIEW 156
13.2 MALE 159
13.3 FEMALE 159
14 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP 161
14.1 OVERVIEW 162
14.2 GERIATRICS 165
14.3 ADULT 165
14.4 PEDIATRICS 166
15 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USER 167
15.1 OVERVIEW 168
15.2 HOSPITAL-BASED LABS 171
15.3 STAND -ALONE LABS 171
15.4 DIAGNOSTIC CHAINS 172
15.5 ACADEMIC INSTITUTES 173
15.6 CLINICAL RESEARCH ORGANISTAION 173
15.7 SPECIALTY DIAGNOSTIC 174
15.8 OTHERS 175
16 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL 176
16.1 OVERVIEW 177
16.2 DIRECT TENDER 180
16.3 RETAIL SALES 180
16.4 THIRD PARTY DISTRIBUTORS 181
16.5 OTHERS 182
17 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION 183
17.1 MIDDLE EAST AND AFRICA 184
17.1.1 SAUDI ARABIA 202
17.1.2 SOUTH AFRICA 215
17.1.3 U.A.E 228
17.1.4 EGYPT 241
17.1.5 ISRAEL 254
17.1.6 REST OF MIDDLE EAST AND AFRICA 267
18 MIDDLE EAST & AFRICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, COMPANY LANDSCAPE 268
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 268
19 COMPANY PROFILES 269
19.1 F. HOFFMANN-LA ROCHE LTD. 269
19.1.1 COMPANY SNAPSHOT 269
19.1.2 REVENUE ANALYSIS 269
19.1.3 COMPANY SHARE ANALYSIS 270
19.1.4 PRODUCT PORTFOLIO 270
19.1.5 RECENT DEVELOPMENT 270
19.2 BIOMERIEUX 271
19.2.1 COMPANY SNAPSHOT 271
19.2.2 REVENUE ANALYSIS 271
19.2.3 COMPANY SHARE ANALYSIS 272
19.2.4 PRODUCT PORTFOLIO 272
19.2.5 RECENT DEVELOPMENTS 272
19.3 SYSMEX CORPORATION 273
19.3.1 COMPANY SNAPSHOT 273
19.3.2 REVENUE ANALYSIS 273
19.3.3 COMPANY SHARE ANALYSIS 274
19.3.4 PRODUCT PORTFOLIO 274
19.3.5 RECENT DEVELOPMENT 274
19.4 BIOMERICA. 275
19.4.1 COMPANY SNAPSHOT 275
19.4.2 REVENUE ANALYSIS 275
19.4.3 COMPANY SHARE ANALYSIS 276
19.4.4 PRODUCT PORTFOLIO 276
19.4.5 RECENT DEVELOPMENT 276
19.5 BIO-RAD LABORATORIES, INC 277
19.5.1 COMPANY SNAPSHOT 277
19.5.2 REVENUE ANALYSIS 277
19.5.3 COMPANY SHARE ANALYSIS 278
19.5.4 PRODUCT PORTFOLIO 278
19.5.5 RECENT DEVELOPMENT 278
19.6 23ANDME, INC. 279
19.6.1 COMPANY SNAPSHOT 279
19.6.2 REVENUE ANALYSIS 279
19.6.3 PRODUCT PORTFOLIO 280
19.6.4 RECENT DEVELOPMENTS 280
19.7 ABBOTT 281
19.7.1 COMPANY SNAPSHOT 281
19.7.2 REVENUE ANALYSIS 281
19.7.3 PRODUCT PORTFOLIO 282
19.7.4 RECENT DEVELOPMENT 282
19.8 ADMERA HEALTH 283
19.8.1 COMPANY SNAPSHOT 283
19.8.2 PRODUCT PORTFOLIO 283
19.8.3 RECENT DEVELOPMENT 283
19.9 AGENDIA. 284
19.9.1 COMPANY SNAPSHOT 284
19.9.2 PRODUCT PORTFOLIO 284
19.9.3 RECENT DEVELOPMENT 284
19.10 AMBRY GENETICS 285
19.10.1 COMPANY SNAPSHOT 285
19.10.2 PRODUCT PORTFOLIO 285
19.10.3 RECENT DEVELOPMENT 286
19.11 BD 287
19.11.1 COMPANY SNAPSHOT 287
19.11.2 REVENUE ANALYSIS 287
19.11.3 PRODUCT PORTFOLIO 288
19.11.4 RECENT DEVELOPMENTS 288
19.12 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER) 289
19.12.1 COMPANY SNAPSHOT 289
19.12.2 REVENUE ANALYSIS 289
19.12.3 PRODUCT PORTFOLIO 290
19.12.4 RECENT DEVELOPMENTS 290
19.13 BGI. 291
19.13.1 COMPANY SNAPSHOT 291
19.13.2 PRODUCT PORTFOLIO 291
19.13.3 RECENT DEVELOPMENT 292
19.14 BIODESIX. 293
19.14.1 COMPANY SNAPSHOT 293
19.14.2 REVENUE ANALYSIS 293
19.14.3 PRODUCT PORTFOLIO 294
19.14.4 RECENT DEVELOPMENTS 294
19.15 EUROFINS SCIENTIFIC 295
19.15.1 COMPANY SNAPSHOT 295
19.15.2 REVENUE ANALYSIS 295
19.15.3 PRODUCT PORTFOLIO 296
19.15.4 RECENT DEVELOPMENT 296
19.16 GUARDANT HEALTH 297
19.16.1 COMPANY SNAPSHOT 297
19.16.2 REVENUE ANALYSIS 297
19.16.3 PRODUCT PORTFOLIO 298
19.16.4 RECENT DEVELOPMENTS 298
19.17 HOLOGIC, INC. 299
19.17.1 COMPANY SNAPSHOT 299
19.17.2 REVENUE ANALYSIS 299
19.17.3 PRODUCT PORTFOLIO 300
19.17.4 RECENT DEVELOPMENT 300
19.18 MILAB SCIENTIFIC. 301
19.18.1 COMPANY SNAPSHOT 301
19.18.2 PRODUCT PORTFOLIO 301
19.18.3 RECENT DEVELOPMENT 301
19.19 NEOGENOMICS LABORATORIES 302
19.19.1 COMPANY SNAPSHOT 302
19.19.2 REVENUE ANALYSIS 302
19.19.3 PRODUCT PORTFOLIO 303
19.19.4 RECENT DEVELOPMENTS 303
19.20 OPKO HEALTH, INC. 304
19.20.1 COMPANY SNAPSHOT 304
19.20.2 REVENUE ANALYSIS 304
19.20.3 PRODUCT PORTFOLIO 305
19.20.4 RECENT DEVELOPMENT 305
19.21 QIAGEN 306
19.21.1 COMPANY SNAPSHOT 306
19.21.2 REVENUE ANALYSIS 306
19.21.3 PRODUCT PORTFOLIO 307
19.21.4 RECENT DEVELOPMENTS 307
19.22 QUEST DIAGNOSTICS INCORPORATED. 308
19.22.1 COMPANY SNAPSHOT 308
19.22.2 REVENUE ANALYSIS 308
19.22.3 PRODUCT PORTFOLIO 309
19.22.4 RECENT DEVELOPMENTS 309
19.23 SEEGENE INC 310
19.23.1 COMPANY SNAPSHOT 310
19.23.2 REVENUE ANALYSIS 310
19.23.3 PRODUCT PORTFOLIO 311
19.23.4 RECENT DEVELOPMENT 311
19.24 SIEMENS HEALTHCARE GMBH 312
19.24.1 COMPANY SNAPSHOT 312
19.24.2 REVENUE ANALYSIS 312
19.24.3 PRODUCT PORTFOLIO 313
19.24.4 RECENT DEVELOPMENT 313
20 QUESTIONNAIRE 314
21 RELATED REPORTS 318
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security